Trial Profile
Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 27 Apr 2017 Status changed from recruiting to discontinued.
- 09 Jun 2016 Planned End Date changed from 1 Jul 2018 to 1 May 2017.
- 09 Jun 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2016.